LD MICRO June 4, 2018 | OTCQB:NMUS

This presentation contains “forward-looking statements”, including statements regarding NemusBioscience, Inc. and its subsidiaries, within the meaning of the “safe harbor” provisions of thePrivate Securities Litigation Reform Act of 1995. All of the statements in this presentation,whether written or oral, that refer to expected or anticipated future actions and results of NEMUSare forward-looking statements. In addition, any statements that refer to expectations,projections, or other characterizations of future events or circumstances are forward-lookingstatements. These forward-looking statements reflect our current projections and expectationsabout future events as of the date of this presentation. NEMUS cannot give any assurance thatsuch forward-looking statements will prove to be correct. The reader is cautioned not to placeundue reliance on these forward-looking statements.

The information provided in this presentation does not identify or include any risk or exposures,of NEMUS that would materially adversely affect the performance or risk of the company. For adescription of the risks and uncertainties related to the business of NEMUS, see our AnnualReport on Form 10-K filed with the Securities and Exchange Commission and our subsequentperiodic reports filed with the Securities and ExchangeCommission.

All information contained in this presentation is provided as of the date of the presentation and issubject to change without notice. Neither NEMUS, nor any other person undertakes anyobligation to update or revise publicly any of the forward-looking statements set out herein,whether as a result of new information, future events or otherwise, except as required by law. Thispresentation shall not constitute an offer to sell or the solicitation of an offer to sell or thesolicitation of an offer to buy any securities of Nemus, nor shall there be any sale of securities inany jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration orqualification under the securities laws of any such jurisdiction. This is presented as a source ofinformation and not an investment recommendation.

Legal Disclaimer

Improving health throughcannabinoid-based therapies

BRIAN MURPHY, MD, MPH, MBAChief Executive Officer

4

A global cannabis investment company focused on the medicinal potential of cannabis and cannabinoids

A leading biopharmaceutical company focused on the development of cannabinoid-based therapeutics

Partnership Highlights

NEMUS and Emerald Health Sciences

• Built on the value of Nemus’ intellectual capital and exclusive agreement with UM for novel cannabinoid technologies

• EHS BOD Committee provides access to key clinical and development expertise

• Ability to leverage EHS financial and life science network to advance development programs

5

The only entity in the US authorized to cultivate cannabis on behalf of the federal government for 50 years

NEMUS has exclusive, perpetual, worldwide exclusivity for all compounds from UM

Global patent estate

OLE’ MISS: Leading Cannabis Research in the US for Over 50 Years

NB1111For the Treatment of

Glaucoma

7

Glaucoma: A Global Cause of Blindness

• Glaucoma is a leading cause of blindness globally with more than 70 million patients affected worldwide.2

• Damage to the retinal ganglion cells (RGCs) is irreversible so therapy is designed to slow disease progression by lowering IOP and thereby preserving remaining vision. 3

• Current therapies work by lowering IOP thus enhancing drainage of fluid from the eye via canals in the anterior chamber or by decreasing fluid production. 1

• African Americans are at highest risk of developing glaucoma in the US. 4

1.WeinrebR, et al; JAMA, 2014; 311(18): 1901-19112.Quigley HA, et al; Br J Ophthalmol, 2006; 90(3): 262-2673.NickellsRW, et al; Ann Rev NeuroSci, 2012; 35:153-1794.Kwon YH, et al; NEJM, 2009; 360(11): 1113-1124

8

Current Therapies Reduce IOP but Lack Direct Neuroprotection

Class of Medication

Example IOP Response Rates*

Local Adverse Effects Systemic Adverse Effects

Prostaglandins Latanoprost 6-8 mm Hg macular edema, conjunctival hyperemia, discoloration of iris

headaches

Prostaglandin Analog

Latanoprostenebunod

7-9 mm Hg iris and local tissue pigmentation, eyelash stimulation, conjunctival hyperemia, eye irritation, eye pain, and instillation site pain

---

β-AndrenergicBlockers

Timolol 5-6 mm Hg ocular irritation and dry eyes contraindicated in asthma, COPD and bradycardia

⍺-Adrenergic Blockers

Brimonidine 4-6 mm Hg ocular irritation, dry eyes and allergic reactions

central nervous effects and respiratory arrest in young children; renal/hepatic failure

Carbonic Anhydrase Inhibitors

Dorzolamide 3-5 mm Hg ocular irritation, dry eyes, burning sensation paresthesia, nausea, diarrhea, loss of appetite, renal stones

Cholinergic Agonists

Pilocarpine 3-7 mm Hg ocular irritation, induced myopia and decreased vision due to ciliary spasm

ciliary spasm leading to headaches

Rho kinase inhibitor

Netarsudil Up to 5 mm Hg conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage

---

Adapted from Weinrb RM et al, JAMA. 2014; 311(18): 1901-1911*IOP response rates taken from Product Inserts for listed medicinals

Despite improvements in IOP management, no currently approved drugs demonstrate direct neuroprotection of retinal ganglion cells (RGCs), which leads to eventual blindness in patients

9

Cannabinoids and Glaucoma

• The cannabis plant contains over 100 cannabinoid-class chemical entities that have been used over centuries in managing multiple medical problems.1

• The main constitutive molecule, delta-9-tetrahydrocannabinol (Δ9-THC), was isolated and structure determined in the early 1960’s.2

• The first report assessing effect of cannabis on IOP appeared in 1971.

• Further human studies using routes of administration that included inhalational, oral, and IV access showed IOP reductions in both normal controls and as high as a 65% decline in patients with glaucoma. 3-6

1. Tomida I, et al., Br J Opthalmol, 2004; 88: 708-7132. Elsohly MA; Cannabis and Cannibinoids; New York: Haworth press, 2002; pgs 75-863. Hepler RS, Frank IR; JAMA, 1971; 217:13924. Cooler p et al; Southern Med J, 1977; 78:9515. Green K et al; Proc Soc Exp Biol and Med, 1977; 154:2286. Goldberg I et al; Australian J opthalmol, 1979; 7(2):151-157

10

NEMUS is developing an optimized cannabinoid technology that enhances bioavailability and offers more predictable pharmacokinetics

Proprietary NEMUS Technology

THC THC-Val-HS(NB1111)

Biochemically Engineered Technology

*Development of delta-9 THC amino acid-dicarboxylate prodrug with improved ocular bioavailability. Invest Ophthalmol Vis Sci 2017; 58:2167-217

Amide-Ester

PROPRIETARY CANNABINOID-BASED THERAPEUTICS

THCVHS BROAD PATENT ESTATE NEMUS GLOBAL RIGHTS

11

Cannabinoids Demonstrate Efficacy & Neuroprotection

Glaucoma Represents a Significant Global Unmet Medical Need

* IMS; 2016

NB1111

Large Market Opportunity High Unmet Medical Need

• $3+ billion globally and growing with aging populations

• $2.6 billion US market (35 MM Rx)*

• Cannabinoids have exhibited neuroprotective qualities in vitro and in vivo (multiple animal species) related to preservation of the optic nerve

• A leading cause of irreversible blindness in the US due to death of retinal ganglion cells (RGS)

NB1111Mechanism of Action

13

• Modulation of cannabinoid receptor tone

already exists by virtue of the

endocannabinoid system located in the eye and other organs

• CB1 receptors display a higher density in the anterior compartment than the posterior (1)

• CB1 receptors have been localized to

ciliary epithelium, ciliary muscle,

trabecular meshwork, canal of Schlemm,

iris; organs that help regulate intra-ocular

pressure (IOP) (2)

• CB2 receptors are more prevalent in the posterior compartment of the eye (1)

1. Porcella A et al; Eur J Neuroscience, 2000; 12:1123-1127

2. Chien FY, et al. Arch Ophthal, 2003; 121:87-90

3. Wei Y, et al. Molecular Vision, 2009; 15: 1243-1251

Cannabinoid receptors are located in the key ocular tissues that regulate IOP

14*Goutham R, et al. IVOS, 2017; 58(4): 2167-2179

• Experiments have shown that NB1111 does not substantively bind CB receptors• The physiological effect comes from THC derived from the prodrug• Pivotal for patent to show proof of prodrug

NB1111 (THCVHS) vs THC: CB receptor dynamics support NB1111 as a prodrug

15*Development of delta-9 THC amino acid-dicarboxylate prodrug with improved ocular bioavailability. Invest Ophthalmol Vis Sci 2017; 58:2167-217

NB1111 exhibited greater permeability into the eye vs. THC

NB1111 (TCHVHS) Achieves Improved Permeability into the Eye vs. THC in Ocular Surfactant* Model

*HPβCD = 2-hydroxy propyl-beta-cyclodextrin

16

No THC or 11-OH-THC was detected in the plasma of study animals even after 5 days of dosing (ng sensitivity level of detection)

NB1111 (THCVHS) Achieves Tissue Penetration in Organs Regulating IOP in Glaucoma Model

17*Goutham R, et al. IVOS, 2017; 58(4): 2167-2179

NB1111 (THCVHS) vs pilocarpine and timolol achieves 45% reduction in IOP*

18

Data reveals the following:

• THCVHS in Tocrisolve exhibits IOP maximum decline of 47%

• THCVHS in SLN exhibits IOP maximum decline of 35%

• THC in SLN exhibited roughly 8-10% decline in IOP

• Encapsulating THCVHS in an SLN enhanced the half-life by almost doubling the time of physiologic effect

NB1111 (THCVHS) achieves significant decline in IOP using SLN (solid lipid nanoparticle) technology

19

Mechanism of Action: Fluid Dynamics

Drug Class

Increased flow

Trabecularmesh

Increased uveoscleral

outflow

Decreased fluid production

Direct Neuroprotection

Prostaglandins

Prostaglandin Analog

β- adrenergic blockers

α- adrenergic agonists

Carbonic anhydrase inhibitors

Cholinergic agonists

Rho kinase inhibitor

NB1111(THCVHS)

NB1111 Fluid Dynamics Has Competitive Advantage Over Currently Available Therapies

NB1111 targets multiple mechanisms to reduce IOP. Associated NEUROPROTECTIVEqualities of THC may also PROTECT against BLINDNESS in glaucoma

20

• Cannabinoid agonists have shown both a clear hypotensive and neuroprotective effect on retinal ganglion cells

• CB1 receptors to a greater extent than CB2 receptors, have been implicated in mediating cannabinoid-induced neuroprotection

• Experimentally, in multiple animal species, synthetic and endogenous cannabinoids have displayed a protective effect on neurons

Cannabinoids Shown to Be Neuroprotective in Multiple Animal Models

NB1111Development Plan

22

Advancing to Clinical Studies: NB1111

Patients with Glaucoma

Initiating in near term

NB1111

Anticipated dosing design will permit patients to act as their own controls (contra-lateral eye dosing)

Patients:

Timeline:

Therapy:

Dosing:

Perform Phase 1b/2a clinical studies in

patients utilizing sites in Australia to generate safety, efficacy, and

pharmacokinetic data

Objective NB1111 Clinical Study

• Australia offers centers of excellence with a pool of qualifying patients as well as economic incentives that when leveraged, could possibly lead to expedited enrollments and quality data

• Nemus has identified an API synthesis partner in AMRI which has expertise in cannabinoid manufacturing, scale-up capability, and a global footprint

Traditional single-ascending dose (SAD) and multiple-ascending dose

(MAD) designs consistent with validated regulatory pathways

Study Design:

23

Near-Term Value Creating Milestones for NB1111

Key Development Milestones

• Initiate UM rabbit H2H study

• Scale up process development for API manufacturing of GMP qualified product

• Initiate primate H2H study

• AUS CRO identification

• Pre IND meeting with FDA

• Projected primate data

• Projected neuroprotection data

• Initiate first in human studies in AUS

Q2’18

Q3’18

Q4’18

H1’19

24

Pipeline

Research Preclinical Phase 1

Ocular Indications

THCVHS NB1111 Glaucoma

CBDVHS NB2222

Dry Eye

Macular DegenerationDiabetic Retinopathy

Other Indications

THCVHS NB1222 CINV

CBDVHS NB2111 CIPN

Cannabinoid Platform NB3111 MRSA

25

• NEMUS is the primary development and commercialization partner of the University of Mississippi, drawing on 50 years of intellectual capital in cannabinoid chemistry and physiology from the only entity with a Federal license to directly study cannabinoids

• The proprietary prodrug of THC has a global patent footprint including the world’s largest pharma markets of USA, Japan and the EU

• Developing cannabinoids for the treatment and/or management of acute and chronic diseases

• Currently, the only cannabinoid company with potential cost-effective and enhanced life-cycle scale-up production related to biosynthetic manufacturing of cannabinoids

• The only cannabinoid company with a re-engineered cannabinoid prodrug designed for multiple routes of administration

NEMUS Value Proposition: Disrupting the cannabinoid therapeutic space

Developing Biosynthetic

Cannabinoids

Targeting Unmet Needs in Multi-Billion Dollar Global Markets

Primary Development & Commercialization

Partner with UM

Proprietary Molecule with Global Patent

Footprint

26

2018

Capitalization

1 18/05/25 (proforma, including pending equity grant to management) 2 18/05/25 3 Based on 18/06/01 OTCQB per share prices of $.28

OTCQB All Shareholders Largest Shareholder: Emerald Health Sciences

Common Shares Outstanding 133.2 M1 73.1 M (54%) 2

Options & Warrants 53.4 M1 40.8 M (76%) 2

Fully Diluted 186.6 M 113.9 M (61%)

Market Cap $37.2M3

Base of Operations Long Beach, California & Oxford, Mississippi

27

BRIAN MURPHY, MD, MPH, MBA – Chief Executive Officer; Chief Medical Officer, DirectorDr. Murphy has almost two decades of experience in drug development and evaluation, both from the academic and industry perspective.He most recently served as the CMO of Eiger Biosciences. Previously, Dr. Murphy was CMO at Valeant Pharmaceuticals International (VRX)where his responsibilities also included oversight of Global Medical Affairs, Clinical Development, Biostatistics, and Pharmacovigilance. Dr.Murphy also served as Medical Director, then VP of Marketing and Commercial Strategy of Hepatology for InterMune, Inc. (ITMN). Prior toInterMune, Dr. Murphy was Medical Director of North America for Antivirals/Interferons at Hoffmann-LaRoche. Murphy is board-certifiedin internal medicine and completed his residency at Tufts-New England Medical Center. He served as Chief Medical Resident in the BostonUniversity Internal Medicine program. He went on to complete parallel fellowship tracts at Harvard Medical School (HMS) and theMassachusetts General Hospital in medicine and clinical epidemiology. He also completed a fellowship in Medical Ethics at HMS-Brighamand Women’s Hospital. Dr. Murphy earned his MD, MPH (general public health), and MS (pharmacology) degrees from New York MedicalCollege and is a graduate of the Harvard School of Public Health (MPH in Health Policy and Management). He earned his MBA at theColumbia University Graduate School of Business.

Management

DOUG CESARIO, MBA – Chief Financial OfficerMr. Cesario brings over 15 years of financial and operational experience across many industries. Prior to joining Nemus, Mr. Cesario servedas Chief Financial Officer of Kaiser Permanente Foundation Hospitals and Health Plan in the Orange County, California marketplace, wherehe managed the financial performance of the health system with an operating budget of over $1 billion per year. Previously Mr. Cesarioheld various financial leadership positions, including founder of Community Capital Advisory Group, a real estate advisory and investmentcompany; director of Skye Automotive, a private equity fund; and corporate finance associate at both full service and boutique investmentbanking firms. Mr. Cesario earned a Master’s in Business Administration from the UCLA Anderson School of Management.

WENDY CUNNING – Vice President of OperationsMs. Cunning brings over 20 years of extensive expertise in U.S. sales, marketing, global new product development, commercialization, and lifecycle management in the biopharmaceutical industry. Prior to joining Nemus, Ms. Cunning served as Director, New Products, U.S. Eye Care at Allergan, where she led the creation of the business unit strategy for the U.S. ocular franchise. She was the Associate Director of Marketing at Amylin Pharmaceuticals, leading the global life-cycle management for Byetta®. Additionally, she held leadership positions at Valeant Pharmaceuticals, a multi-billion dollar pharmaceutical company, as the global marketing and commercial development lead for both the viral hepatitis and HIV franchises. Prior to joining Valeant, Ms. Cunning worked in Hepsera® marketing at Gilead Sciences and sales in HIV and respiratory medicine at GlaxoSmithKline. Ms. Cunning earned a bachelor's degree in biology from West Virginia University.

28

MAHMOUD A. ELSOHLY, PHD Scientific AdvisorWorld’s foremost expert on the science of cannabinoids. 300+ scientific publications . Research professor at The University of Mississippi.

Jim Heppell, EsqBoard of DirectorsMr. Heppell is the former founder, CEO and director of BC Advantage Life Sciences I fund and is currently a director at a number of public and private life science companies. Mr. Heppell has extensive experience in corporate finance law.

Punit Dhillon, BABoard of Directors Mr. Dhillon is the Co-founder and Director of OnoSec Medical, Inc. and the former Vice President of Finance and Operations at Inovio Pharmaceuticals, Inc. He has extensive management experience spanning corporate finance, M&A and strategy implementation.

Avtar Dhillon, MDExecutive Chairman of Emerald and Strategic Advisor to NemusDr. Dhillon is currently the Executive Chairman for Emerald Life Sciences and the former President and CEO of Inovio Pharmaceutics Inc. He is a life sciences entrepreneur with more than 20 years’ experience building public companies.

DONALD I. ABRAMS, M.D. Scientific AdvisorChief, Hematology/Oncology at UCSFCancer and Integrative Medicine specialist with research interests in the development of anti-cancer therapeutics and palliative care medicines.

Board of Directors and Strategic Advisors

29

130 North Marina DriveLong Beach, CA 90803

949-396-0330hello@nemusbio.com

www.nemusbioscience.com

Investor Relations:Adam Holdsworth

PCG Advisory Group646-862-4607

adamh@pcgadvisory.com

Contact

Thank you!To learn more please contact: invest@nemusbio.com